|
Childhood Anaplastic Oligodendroglioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype.
|
30878754 |
2019 |
|
Childhood Anaplastic Oligodendroglioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors.
|
30072066 |
2018 |
|
Childhood Anaplastic Oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors.
|
28640702 |
2017 |
|
Childhood Anaplastic Oligodendroglioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The R132H IDH1 mutation was identified in 43/117 tumor samples and R172K IDH2 mutation was detected in only one anaplastic oligodendroglioma.
|
27268645 |
2016 |
|
Childhood Anaplastic Oligodendroglioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Not only morphological and immunohistochemical examinations, but also cytogenetical investigations for IDH1/2 mutation, 1p/19q loss, and PTEN alteration, are strongly supportive methods for the differential diagnosis of small cell glioblastoma and anaplastic oligodendroglioma.
|
23979650 |
2014 |
|
Childhood Anaplastic Oligodendroglioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene.
|
24149775 |
2014 |
|
Childhood Anaplastic Oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combining two biomarkers, IDH1/2 and 1p/19q codeletion, makes it possible to stratify AO in three groups with very distinct prognostic features.
|
23681562 |
2013 |
|
Childhood Anaplastic Oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the six IDH1 positive cases, three were glioblastomas (IV), and one each were anaplastic oligoastrocytoma (III), anaplastic oligodendroglioma III (n=1) and diffuse astrocytoma.
|
24460285 |
2013 |
|
Childhood Anaplastic Oligodendroglioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AOA1 with 1p/19q codeletion and/or IDH1/2 mutation showed similar Kaplan-Meier plots with AO (P = .169 for PFS and P = .523 for OS).
|
23486687 |
2013 |
|
Childhood Anaplastic Oligodendroglioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We determined the effect of IDH1 mutations on progression-free survival and overall survival (OS), and its correlation with other clinical and molecular features in the prospective randomized European Organization for Research and Treatment of Cancer study 26951 on adjuvant procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) in anaplastic oligodendroglioma.
|
20160062 |
2010 |